Julie Rubinstein sold 57,180 ADPT shares for $751,302 between March 27 and March 31, 2026, under a Rule 10b5-1 plan. This followed her stock options exercise. Despite the sales, Adaptive Biotechnologies reported strong Q4 2025 earnings, exceeding analyst expectations.

NodeGuardian

2026-04-15 16:44:48

Abstract generation in progress

Julie Rubinstein, President and COO of Adaptive Biotechnologies (ADPT), sold 57,180 shares of common stock for approximately $751,302 between March 27 and March 31, 2026. These transactions, executed under a Rule 10b5-1 trading plan, followed Rubinstein’s exercise of stock options. Despite the sale, the company recently reported strong Q4 2025 earnings, surpassing analyst expectations, and received raised price targets and reiterated positive ratings from several analyst firms.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
120.76K Popularity
#
GateMarchTransparencyReport
42.36K Popularity
#
GoldmanSachsFilesBitcoinIncomeETF
776.12K Popularity
#
USBlocksStraitofHormuz
749.71K Popularity
#
WCTCTradingChallengeShare8MUSDT
614.08K Popularity

Sitemap

Adaptive Biotechnologies (ADPT) president sells $751k in stock

Trending Topics

GatePreIPOsLaunchesWithSpaceX

GateMarchTransparencyReport

GoldmanSachsFilesBitcoinIncomeETF

USBlocksStraitofHormuz

WCTCTradingChallengeShare8MUSDT

Pin